Site Search
Bill will jump-start rebuilding of the antibiotics pipeline that is vital to stave off a looming pandemic.
The Cystic Fibrosis Foundation has awarded up to $5.6 million to Microbion Corporation to develop a novel, inhaled antibiotic to treat drug-resistant bacterial infections in people with cystic fibrosis.
On Thursday, January 14 at 7 p.m. ET the CF Foundation will host a live town hall where top questions about the COVID-19 vaccines will be answered by a panel of experts. Register here.
FDA issues emergency use authorization for a third COVID-19 vaccine.
The Cystic Fibrosis Foundation has arranged for over 10,000 home spirometers to be provided to care centers to support continued access to high quality, comprehensive care during the COVID-19 pandemic.
The U.S. Food and Drug Administration (FDA) has approved TOBI® Podhaler™ (tobramycin inhalation powder), a dry powder formulation of the antibiotic TOBI, to treat lung infections caused by the bacteria Pseudomonas aeruginosa (P. aeruginosa).